Introduction
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved the first-ever treatment for chronic Hepatitis Delta Virus (HDV) infection. The newly approved drug, Hepcludex (bulevirtide-gmod), offers a long-awaited treatment option for patients living with this rare but severe liver disease. The approval marks a major breakthrough in liver disease management and provides new hope for individuals who previously had no FDA-approved therapies available.
What Is Hepatitis Delta Virus?
Hepatitis Delta Virus is a serious liver infection that occurs only in people who are already infected with the Hepatitis B Virus (HBV). HDV depends on HBV to replicate and spread within the body. Although less common than other forms of viral hepatitis, HDV is considered the most aggressive type because it can rapidly lead to liver scarring, liver failure, liver cancer, and death.
People may contract HDV through exposure to infected blood, unprotected sexual contact, shared needles, or occupational exposure to blood. Vaccination against Hepatitis B can also prevent Hepatitis Delta infection because HDV cannot exist without HBV.
For example, a person with a normal BMI may have a high percentage of body fat and low muscle mass, a condition sometimes referred to as “normal-weight obesity.” Despite appearing healthy according to BMI standards, these individuals may face many of the same health risks associated with traditional obesity.
A Historic Approval
The FDA approved Hepcludex on May 22, 2026, for adults with chronic HDV infection who either have no cirrhosis or have compensated cirrhosis, a stage where the liver is damaged but still functioning adequately. This approval fills a major treatment gap that has existed for decades.
The drug received several special regulatory designations, including Breakthrough Therapy Designation, Orphan Drug Designation, Priority Review, and Accelerated Approval. These programs are designed to speed up the development of treatments for serious diseases with limited options.
The findings revealed that relying solely on BMI can result in a significant underdiagnosis of obesity. Many participants who appeared to have healthy weights showed excessive fat accumulation, particularly around the abdomen, which is known to increase the risk of metabolic and cardiovascular diseases.
How Hepcludex Works
Hepcludex works differently from traditional antiviral medications. The drug blocks a receptor on liver cells known as NTCP (sodium taurocholate co-transporting polypeptide), which both Hepatitis B and Hepatitis Delta viruses use to enter liver cells. By preventing viral entry, Hepcludex helps reduce the spread of infection within the liver.
The treatment is administered as a once-daily subcutaneous injection and can be used at home under medical supervision.
Clinical Trial Results
The FDA’s decision was based primarily on data from the Phase 3 MYR301 clinical trial. Researchers compared patients who received immediate treatment with Hepcludex against those whose treatment was delayed.
Results after 48 weeks showed:
- 48% of treated patients achieved a combined virologic and biochemical response.
- Only 2% of patients in the delayed-treatment group achieved the same response.
- 20% of treated patients had undetectable HDV levels after 48 weeks.
- Viral suppression improved over time, reaching 36% at week 96 and 50% at week 144.
These findings demonstrate that prolonged treatment can significantly reduce viral activity and improve liver health.
Safety Considerations
Like all medications, Hepcludex can cause side effects. Commonly reported reactions include:
- Injection site reactions
- Headache
- Abdominal pain
- Fatigue
- Itching (pruritus)
The drug also carries a boxed warning, the FDA’s strongest safety warning, because stopping treatment may trigger severe flare-ups of both Hepatitis D and Hepatitis B infections. Patients require careful monitoring if therapy is discontinued.
